You just read:

Innovent and Eli Lilly Announce NMPA Acceptance of a Supplemental New Drug Application for Sintilimab in Combination with ALIMTA® (Pemetrexed) and Platinum as First-Line Therapy in Non-squamous NSCLC

News provided by

Innovent Biologics, Inc.

Apr 23, 2020, 19:50 ET